Търсене на изпитвания

AI · Cancer

Намерени 1,993 изпитвания за "Cancer" Стр. 84 от 100

Активно (без набиране) Фаза 3

eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients

Non-small Cell Lung Cancer

The primary purpose of this study is to evaluate the efficacy and safety of X-396 (ensartinib) vs. crizotinib in patients with ALK-positive non-small cell lung cancer that have received up to 1 prior chemotherapy regimen and no prior ALK inhibitor.

Начало: 01.06.2016 Край: 31.12.2025 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +17 Xcovery Holdings, Inc. NCT02767804

Активно (без набиране) Фаза 1

Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer

Non-Small-Cell Lung Cancer

The purpose of study is to evaluate the safety, pharmacokinetics, and preliminary efficacy of Amivantamab as a monotherapy and in combination with lazertinib, and to determine the recommended Phase 2 dose (RP2D) (monotherapy), recommended Phase 2 combination dose (RP2CD) (combination therapy), and to determine recommended Phase 2 Dose (RP2q3W) with combination chemotherapy (Amivantamab in combination with standard of care carboplatin and pemetrexed) in 21 day treatment cycle for participants with advanced non-small cell lung cancer (NSCLC).

Начало: 24.05.2016 Край: 31.12.2026 Възраст: от 18 г. Лечение

Australia, Canada, China +7 Janssen Research & Development, LLC NCT02609776

Активно (без набиране) Фаза 2

A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer

Biliary Tract Cancer Metastatic Cancer Advanced Cancer

The main purpose of this study is to evaluate the efficacy and safety of ramucirumab or merestinib or placebo plus cisplatin and gemcitabine in participants with advanced or metastatic biliary tract cancer.

Начало: 19.05.2016 Край: 01.12.2026 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +13 Eli Lilly and Company NCT02711553

Активно (без набиране) Фаза 1/2

Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer

Triple Negative Breast Cancer

The goal of this study is to establish the safety and tolerability of pembrolizumab when administered in combination with either of two chemotherapy regimens (weekly paclitaxel or capecitabine) in unresectable/metastatic triple negative breast cancer (MTNBC) patients.

Начало: 23.02.2016 Край: 01.12.2026 Възраст: от 18 г.

United States Providence Health & Services NCT02734290

Активно (без набиране)

INTense ExeRcise for SurviVAL Among Men with Metastatic Prostate Cancer (INTERVAL - GAP4)

Metastatic Prostate Cancer

To determine if supervised high intensity aerobic and resistance training increases overall survival compared to self-directed exercise in patients with metastatic prostate cancer.

Начало: 01.01.2016 Край: 01.10.2026 Възраст: от 18 г. Лечение

Australia, Canada, Germany +3 Movember Foundation NCT02730338

Активно (без набиране) Фаза 3

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

Urothelial Cancer

A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 (Durvalumab) Monotherapy and MEDI4736 (Durvalumab) in Combination with Tremelimumab Versus Standard of Care Chemotherapy in Patients with Stage IV Urothelial Cancer

Начало: 02.11.2015 Край: 31.12.2026 Възраст: 18–130 г. Лечение

Australia, Austria, Belgium +21 AstraZeneca NCT02516241

Активно (без набиране) Фаза 3

Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]

Non-Small Cell Lung Cancer

This is a Phase III, global, multicenter, open-label, randomized study to compare the efficacy and safety of 16 cycles (1 cycle duration=21 days) of atezolizumab (MPDL3280A) treatment compared with best supportive care (BSC) in participants with Stage IB-Stage IIIA non-small cell lung cancer (NSCLC) following resection and adjuvant chemotherapy, as measured by disease-free survival (DFS) as assessed by the investigator and overall survival (OS). Participants, after completing up to 4 cycles of adjuvant cisplatin-based chemotherapy, will be randomized in a 1:1 ratio to receive atezolizumab for 16 cycles or BSC.

Начало: 31.10.2015 Край: 31.08.2027 Възраст: от 18 г. Лечение

Australia, Belgium, China +17 Hoffmann-La Roche NCT02486718

Активно (без набиране) Фаза 3

PALbociclib CoLlaborative Adjuvant Study

Breast Cancer

This is a prospective, two arm, international, multicenter, randomized, open-label Phase III study evaluating the addition of 2 years of palbociclib to standard adjuvant endocrine therapy for patients with HR+ / HER2- early breast cancer (EBC). The purpose of the PALLAS study is to determine whether the addition of palbociclib to adjuvant endocrine therapy will improve outcomes over endocrine therapy alone for HR+/HER2- early breast cancer. Assessment of a variety of correlative analysis, including evaluation of the effect of palbociclib in genomically defined tumor subgroups, is planned.

Начало: 01.08.2015 Край: 01.12.2028 Възраст: от 18 г. Лечение

Australia, Belgium, Canada +15 Alliance Foundation Trials, LLC. NCT02513394

Активно (без набиране) Фаза 3

Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia

Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA

This phase III trial studies tretinoin and arsenic trioxide in treating patients with newly diagnosed acute promyelocytic leukemia. Standard treatment for acute promyelocytic leukemia involves high doses of a common class of chemotherapy drugs called anthracyclines, which are known to cause long-term side effects, especially to the heart. Tretinoin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Arsenic trioxide may stop the growth of cancer cells by either killing the cells, by stopping them from dividing, or by stopping them from spreading. Completely removing or reducing the amount of anthracycline chemotherapy and giving tretinoin together with arsenic trioxide may be an effective treatment for acute promyelocytic leukemia and may reduce some of the long-term side effects.

Начало: 21.07.2015 Край: 30.06.2029 Възраст: 12–21 г. Лечение

Australia, Canada, New Zealand +3 Children's Oncology Group NCT02339740

Активно (без набиране)

Comparison of Expression of Carcinogenesis-related Molecular Markers in the Patients With Colon Cancer and Polyp

Colorectal Cancer Colorectal Adenoma

A study of carcinogenesis-related molecular markers in the patients with colorectal cancer and colorectal adenoma.

Начало: 01.03.2015 Край: 01.12.2026 Възраст: от 18 г.

South Korea Seoul National University Bundang Hospital NCT05638542

Активно (без набиране) Фаза 3

Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

Lung Non-Squamous Non-Small Cell Carcinoma Stage IB Lung Non-Small Cell Carcinoma AJCC v7 Stage II Lung Non-Small Cell Cancer AJCC v7 Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 +2

This phase III ALCHEMIST trial studies how well erlotinib hydrochloride compared to observation works in treating patients with stage IB-IIIA non-small cell lung cancer that has been completely removed by surgery (resected). Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Начало: 11.02.2015 Край: 03.02.2027 Възраст: от 18 г.

Puerto Rico, United States National Cancer Institute (NCI) NCT02193282

Активно (без набиране)

Compass - Randomised Controlled Trial of Primary HPV Testing for Cervical Screening in Australia

Cancer of the Cervix Cervical Intraepithelial Neoplasia

Compass is a randomised controlled trial of primary HPV testing for cervical cancer screening in Australia. A pilot study involving 5,000 women was carried out in 2013-2014. The trial will involve recruiting 76,300 women from primary health clinics. Women aged 25-69, attending for cervical screening or for routine follow-up will be invited to participate in the 2-arm trial. A liquid-based cytology (LBC) sample will be taken from consenting women and sent to VCS Pathology. Women will be randomised in a 1:2 parallel group allocation to LBC and HPV arms using randomisation with the minimisation procedure, with stratification by birth cohort according to whether offered HPV vaccination in Australia's national publicly-funded HPV vaccination program (date of birth \>=July 1st 1980 and \

Начало: 01.01.2015 Край: 01.03.2037 Възраст: 25–69 г. Скрининг

Australia VCS Foundation NCT02328872

Активно (без набиране) Фаза 3

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

Hormone Sensitive Prostate Cancer Prostate Cancer Cancer of the Prostate

The purpose of this study is to assess enzalutamide plus leuprolide in patients with high-risk nonmetastatic prostate cancer progressing after radical prostatectomy or radiotherapy or both. The randomized / blinded portion of the study is now completed following primary endpoint analyses. The study remains ongoing in open label format.

Начало: 17.12.2014 Край: 19.09.2026 Възраст: от 18 г. Лечение

Australia, Brazil, Canada +13 Pfizer NCT02319837

Активно (без набиране) Фаза 3

A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer

Breast Cancer

The main purpose of this study is to evaluate how effective nonsteroidal aromatase inhibitors (NSAI) plus abemaciclib are in postmenopausal women with breast cancer. Participants will be randomized to abemaciclib or placebo in a 2:1 ratio.

Начало: 06.11.2014 Край: 01.12.2026 Възраст: от 18 г. Лечение

Australia, Belgium, Canada +18 Eli Lilly and Company NCT02246621

Активно (без набиране) Фаза 1

Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM

Glioblastoma

This research study is studying a new type of vaccine as a possible treatment for patients with glioblastoma. This research study is a Phase I clinical trial, which tests the safety of an investigational intervention and also tries to define the appropriate dose of the intervention to use for further studies. "Investigational" means that the intervention is being studied and that research doctors are trying to find more about it. It also means that the FDA (U.S. Food and Drug Administration) has not approved the Personalized NeoAntigen Cancer Vaccine for any use in patients, including people with glioblastoma. The purpose of the initial study cohort (Cohort 1) is to determine if it is possible to make and administer safely a vaccine against glioblastoma by using information gained from specific characteristics of the participants tumor. It is known that glioblastomas have mutations (changes in genetic material) that are specific to an individual patient's tumor. These mutations can cause the tumor cells to produce proteins that appear very different from the body's own cells. It is possible that these proteins used in a vaccine may induce strong immune responses, which may help the body fight any tumor cells that could cause the glioblastoma to come back in the future. Three additional cohorts (1a, 1b, \& 1c) were added to the study following completion of accrual to the original study cohort (cohort 1). Each new cohort receives NeoVax and radiation therapy as administered to cohort 1 and will also receive pembrolizumab: cohort 1a patients will start pembrolizumab w/in 2 weeks after start of RT, and continue every 3 weeks for up to 2 years; cohort 1b patients will start pembrolizumab 2-4 weeks after completion of NeoVax priming, and continue every 3 weeks for up to 2 years; cohort 1c patients will receive a single dose of pembrolizumab administered within 2 weeks after start of RT, re-start 2-4 weeks after completion of NeoVax priming, and continue every 3 weeks for up to 2 years. The rationale for adding these new cohorts is: 1) to assess the safety and feasibility of NeoVax when administered with pembrolizumab; and 2) to determine if the timing of anti-PD-1 administration impacts the immunogenicity of NeoVax. An additional sub-study cohort (1d) is being added for patients whose tumor is MGMT-methylated. Cohort 1d will enroll patients with tumors for which the MGMT status is methylated or partially methylated; patients on cohort 1d will receive standard daily temozolomide during radiation and as adjuvant therapy for up to six cycles following completion of radiation therapy. The rationale for adding cohort 1d is to determine the safety and feasibility of NeoVax when administered with pembrolizumab and temozolomide.

Начало: 01.11.2014 Край: 01.02.2028 Възраст: от 18 г.

United States Dana-Farber Cancer Institute NCT02287428

Активно (без набиране)

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Stage IB Lung Non-Small Cell Carcinoma AJCC v7 Stage II Lung Non-Small Cell Cancer AJCC v7 Stage IIA Lung Cancer AJCC v8 Stage IIB Lung Cancer AJCC v8 +3

This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.

Начало: 26.09.2014 Край: 28.09.2026 Възраст: от 18 г.

Guam, Puerto Rico, United States National Cancer Institute (NCI) NCT02194738

Активно (без набиране)

POSNOC - A Trial Looking at Axillary Treatment in Early Breast Cancer

Breast Cancer

POSNOC is a pragmatic, randomised, multicentre, non-inferiority trial. Aim For women with early stage breast cancer and one or two sentinel node macrometastases, to assess whether adjuvant therapy alone is no worse than adjuvant therapy plus axillary treatment, in terms of axillary recurrence within 5 years. Stratification: Institution, Age (\

Начало: 01.08.2014 Край: 31.12.2026 Възраст: от 18 г. Лечение

Australia, New Zealand, United Kingdom University Hospitals of Derby and Burton NHS Foundation NCT02401685

Активно (без набиране) Фаза 3

A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer

Breast Neoplasms

The main purpose of this study is to compare progression-free survival for women with hormone receptor positive (HR+), human epidermal growth factor receptor (HER2) negative advanced breast cancer receiving either abemaciclib + fulvestrant or fulvestrant alone. Participants will be randomized to abemaciclib or placebo in a 2:1 ratio. The study will last about 9 months for each participant. For the endocrine naïve cohort, all participants will received abemaciclib + fulvestrant.

Начало: 22.07.2014 Край: 01.12.2027 Възраст: от 18 г. Лечение

Australia, Belgium, Canada +16 Eli Lilly and Company NCT02107703

Активно (без набиране) Фаза 3

Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer

Breast Cancer

Olaparib treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy

Начало: 22.04.2014 Край: 28.05.2029 Възраст: 18–130 г. Лечение

Argentina, Australia, Belgium +18 AstraZeneca NCT02032823

Активно (без набиране) Фаза 3

Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer

Prostatic Neoplasms

The purpose of this study is to determine the effectiveness of enzalutamide, versus a conventional non-steroidal anti androgen (NSAA), when combined with a luteinizing hormone releasing hormone analog (LHRHA) or surgical castration, as first line androgen deprivation therapy (ADT) for newly diagnosed metastatic prostate cancer.

Начало: 01.03.2014 Край: 30.06.2027 Възраст: от 18 г. Лечение

Australia, Canada, Ireland +3 University of Sydney NCT02446405

1 … 82 83 84 85 86 … 100